Abstract
Sweet syndrome (SS), the prototypical neutrophilic dermatosis, is characterized by abrupt onset of tender plaques and nodules, classically accompanied by fever and leukocytosis. While management mainly relies on systemic corticosteroids, inadequate response can be seen in some patients that necessitates exploring other treatment options. Early diagnosis of malignancy-associated SS (MA-SS) along with detection of concomitant malignancy is crucial for improving patients’ outcomes. Data regarding various clinical manifestations, extracutaneous associations, treatment, and outcomes are poorly characterized in the literature. We aimed to review all published case reports and case series to portray clinical features of SS including extracutaneous manifestations. We also describe reported treatment options and their outcomes to draw attention toward unmet therapeutic needs in the management of SS. In addition, for clinical and practical purposes, we attempted to delineate the distinction between MA-SS and nonmalignant subtypes of SS.
Journal Section:
Wounds and Healing – Research Article
References
1.
Sweet
RD
. An acute febrile neutrophilic dermatosis
. Br J Dermatol
. 1964
;76
:349
–56
.2.
Su
WP
, Liu
HN
. Diagnostic criteria for Sweet’s syndrome
. Cutis
. 1986
;37
(3
):167
–74
.3.
Kemmett
D
, Hunter
JA
. Sweet’s syndrome: a clinicopathologic review of 29 cases
. J Am Acad Dermatol
. 1990
23
Pt 1
503
7
.4.
Van Beek
MJ
, Swerlick
RA
, Mathes
B
, Hruza
GJ
, Resneck
J
Jr, Pak
HS
. The 2020 annual report of DataDerm: the database of the American Academy of Dermatology
. J Am Acad Dermatol
. 2021
;84
(4
):1037
–41
.5.
Cohen
PR
, Kurzrock
R
. Sweet’s syndrome: a neutrophilic dermatosis classically associated with acute onset and fever
. Clin Dermatol
. 2000
;18
(3
):265
–82
.6.
Borges da Costa
J
, Silva
R
, Soares de Almeida
L
, Filipe
P
, Marques Gomes
M
. Sweet’s syndrome: a retrospective study of 42 admitted patients in a Portuguese hospital
. Int J Dermatol
. 2009
;48
(9
):953
–5
.7.
Cohen
PR
, Kurzrock
R
. Sweet’s syndrome revisited: a review of disease concepts
. Int J Dermatol
. 2003
;42
(10
):761
–78
.8.
Weiss
EH
, Ko
CJ
, Leung
TH
, Micheletti
RG
, Mostaghimi
A
, Ramachandran
SM
. Neutrophilic dermatoses: a clinical update
. Curr Dermatol Rep
. 2022
;11
(2
):89
–102
.9.
Amouri
M
, Masmoudi
A
, Ammar
M
, Boudaya
S
, Khabir
A
, Boudawara
T
. Sweet’s syndrome: a retrospective study of 90 cases from a tertiary care center
. Int J Dermatol
. 2016
;55
:1033
–9
.10.
Cohen
PR
, Kurzrock
R
. Sweet’s syndrome and cancer
. Clin Dermatol
. 1993
;11
(1
):149
–57
.11.
Nelson
CA
, Noe
MH
, McMahon
CM
, Gowda
A
, Wu
B
, Ashchyan
HJ
. Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center
. J Am Acad Dermatol
. 2018
;78
(2
):303
9.e4
.12.
Nofal
A
, Abdelmaksoud
A
, Amer
H
, Nofal
E
, Yosef
A
, Gharib
K
. Sweet’s syndrome: diagnostic criteria revisited
. J Dtsch Dermatol Ges
. 2017
;15
(11
):1081
–8
.13.
Wallach
D
, Vignon-Pennamen
MD
. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses
. Br J Dermatol
. 2018
;178
(3
):595
–602
.14.
Ajili
F
, Souissi
A
, Bougrine
F
, Boussetta
N
, Abdelhafidh
NB
, Sayhi
S
. Coexistence of pyoderma gangrenosum and sweet’s syndrome in a patient with ulcerative colitis
. Pan Afr Med J
. 2015
;21
:151
.15.
Salem
I
, Kimak
M
, Conic
R
, Bragazzi
NL
, Watad
A
, Adawi
M
. Neutrophilic dermatoses and their implication in pathophysiology of asthma and other respiratory comorbidities: a narrative review
. Biomed Res Int
. 2019
;2019
:7315274
.16.
Borda
LJ
, Wong
LL
, Marzano
AV
, Ortega-Loayza
AG
. Extracutaneous involvement of pyoderma gangrenosum
. Arch Dermatol Res
. 2019
;311
(6
):425
–34
.17.
Rochet
NM
, Chavan
RN
, Cappel
MA
, Wada
DA
, Gibson
LE
. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients
. J Am Acad Dermatol
. 2013
;69
(4
):557
–64
.18.
Heath
MS
, Ortega-Loayza
AG
. Insights into the pathogenesis of sweet’s syndrome
. Front Immunol
. 2019
;10
:414
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
